Age has an important impact, with younger women have a higher pretreatment AMH, and a lower risk of undetectable AMH at the end of treatment chemotherapy (65% in women treated for breast cancer aged over 40; 16% in women aged ≤40 years) [22▪▪]. Here, AMH is linked to breast carcinoma.